Vintafolide: A novel targeted therapy for the treatment of folate receptor expressing tumors

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 4, 2015, Pages 206-218

  Vergote, Ignace ^a   Leamon, Christopher P ^b  

^a Katholieke Universiteit   (Belgium)

^b Endocyte Inc   (United States)

Author keywords

Folate receptor; Lung neoplasms; Neoplasms; Ovarian neoplasms; Small molecule drug conjugate; Vintafolide

Indexed keywords

FOLATE RECEPTOR; FOLATE RECEPTOR 1; VINTAFOLIDE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; FOLATE METABOLISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; OVARY CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84931327042     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015584763     Document Type: Review

References (68)

1. Ab O. Bartle L. Rui L. Coccia J. Johnson H. Whiteman K. et al. (2011) IMGN853, an anti-folate receptor I antibody-maytansinoid conjugate for targeted cancer therapy. Cancer Res 71: 4576.
2. Allard J. Risinger J. Morrison C. Young G. Rose G. Fowler J. et al. (2007) Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 107: 52–57.
3. Antony A. (1996) Folate receptors. Annu Rev Nutr 16: 501–521.
4. Armstrong D. White A. Weil S. Phillips M. Coleman R. (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 129: 452–458.
5. Beck A. Lambert J. Sun M. Lin K. (2012) Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs 4: 637–647.
6. Bicknell R. (2005) The realisation of targeted antitumour therapy. Br J Cancer 92(Suppl. 1): S2–S5.
7. Bottsford-Miller J. Coleman R. Sood A. (2012) Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30: 4026–4034.
8. Brown J. Neuper C. Clayton A. Mariani A. Konecny G. Thomas M. et al. (2008) Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas. Int J Cancer 123: 1699–1703.
9. Christoph D. Asuncion B. Hassan B. Tran C. Maltzman J. O'Shannessy D. et al. (2013) Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8: 19–30.
10. Crane L. Arts H. van Oosten M. Low P. van der Zee A. van Dam G. et al. (2012) The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol 35: 9–18.
11. Despierre E. Lambrechts S. Leunen K. Berteloot P. Neven P. Amant F. et al. (2013) Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol 130: 192–199.
12. de Vita V. Jr Chu E. (2008) A history of cancer chemotherapy. Cancer Res 68: 8643–8653.
13. Dosio F. Milla P. Cattel L. (2010) EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 11: 1424–1433.
14. Edelman M. Bonomi P. Harb W. Pal S. Boccia R. Kraut M. et al. (2012 a) The co-development of a folate receptor targeted drug conjugate vintafolide (EC145) and a folate receptor targeted imaging agent 99mTc-etarfolatide (EC20) in the treatment of advanced adenocarcinoma NSCLC. J Thorac Oncol 7(Suppl. 1): S63.
15. Edelman M. Harb W. Pal S. Boccia R. Kraut M. Bonomi P. et al. (2012 b) Multicenter trial of EC 145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol 7: 1618–1621.
16. Elnakat H. Ratnam M. (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56: 1067–1084.
17. Elnakat H. Ratnam M. (2006) Role of folate receptor genes in reproduction and related cancers. Front Biosci 11: 506–519.
18. Farrell C. Schweizer C. Wustner J. Weil S. Namiki M. Nakano T. et al. (2012) Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemother Pharmacol 70: 727–734.
19. Feliz L. Tsimberidou A. (2013) Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 72: 1–12.
20. Giuliano S. Pages G. (2013) Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95: 1110–1119.
21. Gokhale M. Thakur A. Rinaldi F. (2012) Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev Ind Pharm 39: 1315–1327.
22. Gonen N. Assaraf Y. (2012) Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 15: 183–210.
23. Hanna N. Juhasz E. Cainap C. Gladkov O. Ramlau R. Juan-Vidal O. et al. (2014) TARGET: a randomized phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive nonsmall cell lung cancer (NSCLC) patients. Ann Oncol 25(Suppl. 5): v1–v41; abstract LBA40_PR.
24. Hartmann L. Keeney G. Lingle W. Christianson T. Varghese B. Hillman D. et al. (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121: 938–942.
25. Ifergan I. Assaraf Y. (2008) Molecular mechanisms of adaptation to folate deficiency. Vitam Horm 79: 99–143.
26. Imai K. Takaoka A. (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714–727.
27. Jelovac D. Armstrong D. (2012) Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des 18: 3812–3815.
28. Kalli K. Oberg A. Keeney G. Christianson T. Low P. Knutson K. et al. (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108: 619–626.
29. Kamen B. Capdevila A. (1986) Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci U S A 83: 5983–5987.
30. Kamen B. Smith A. (2012) Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 70: 113–120.
31. Kirkjian C. LoRusso P. Sankhala K. Birrer M. Kirby M. Ladd S. et al. (2013) A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN 853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors. J Clin Oncol 31(Suppl.): abstract 2573.
32. Konner J. Bell-McGuinn K. Sabbatini P. Hensley M. Tew W. Pandit-Taskar N. et al. (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288–5295.
33. Leamon C. Reddy J. Vlahov I. Westrick E. Dawson A. Dorton R. et al. (2007 a) Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharmacol 4: 659–667.
34. Leamon C. Reddy J. Bloomfield A. Dorton R. Nelson M. Klein P. et al. (2012) Predicting response to EC 145 therapy using the folate receptor-specific radiodiagnostic imaging agent, 99mTc-EC20. Cancer Res 72(Suppl. 1): 3622.
35. Leamon C. Reddy J. Vlahov I. Westrick E. Parker N. Nicoson J. et al. (2007 b) Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC 140 and EC145. Int J Cancer 121: 1585–1592.
36. Li J. Sausville E. Klein P. Morgenstern D. Leamon C. Messmann R. et al. (2009) Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC 145 in cancer patients. J Clin Pharmacol 49: 1467–1476.
37. LoRusso P. Edelman M. Bever S. Forman K. Pilat M. Quinn M. et al. (2012) Phase I study of folate conjugate EC 145 (vintafolide) in patients with refractory solid tumors. J Clin Oncol 30: 4011–4016.
38. Miller M. Foy K. Kaumaya P. (2013) Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 15: 166–176.
39. Moore K. Ponte J. LoRusso P. Birrer M. Bauer T. Borghaei H. et al. (2014) Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors. J Clin Oncol 32(Suppl.): abstract 5571.
40. Morris R. Naumann R. Shah N. Mauer A. Strauss H. Uszler M. et al. (2014) Phase 2 study of treatment of advanced ovarian cancer with folate receptor targeted therapeutic (vintafolide) and companion SPECT based imaging agent (99mTc-etarfolatide). Ann Oncol 25: 852–858.
41. Naumann R. Coleman R. Burger R. Sausville E. Kutarska E. Ghamande S. et al. (2013) Precedent: a randomized phase II trial comparing EC 145 (vintafolide) and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in patients with platinum-resistant ovarian cancer. J Clin Oncol 31: 4400–4406.
42. Nunez M. Behrens C. Woods D. Lin H. Suraokar M. Kadara H. et al. (2012) High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 7: 833–840.
43. Parker N. Turk M. Westrick E. Lewis J. Low P. Leamon C. (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: 284–293.
44. Paulos C. Reddy J. Leamon C. Turk M. Low P. (2004) Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 66:1406–1414.
45. Pribble P. Edelman M. (2012) EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Invest Drugs 21: 755–761.
46. Ratnam M. Marquardt H. Duhring J. Freisheim J. (1989) Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 28: 8249–8254.
47. Reddy J. Dorton R. Bloomfield A. Nelson M. Vetzel M. Guan J. et al. (2014) Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs. Clin Cancer Res 20: 2104–2114.
48. Reddy J. Dorton R. Westrick E. Dawson A. Smith T. Xu L. et al. (2007) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67: 4434–4442.
49. Ross J. Chaudhuri P. Ratnam M. (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: 2432–2443.
50. Salazar M. Ratnam M. (2007) The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 26: 141–152.
51. Shen F. Ross J. Wang X. Ratnam M. (1994) Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33: 1209–1215.
52. Shia J. Klimstra D. Nitzkorski J. Low P. Gonen M. Landmann R. et al. (2008) Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 39: 498–505.
53. Spiegelstein O. Eudy J. Finnell R. (2000) Identification of two putative novel folate receptor genes in humans and mouse. Gene 258: 117–125.
54. Stegmeier F. Warmuth M. Sellers W. Dorsch M. (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 87: 543–552.
55. Tang J. Salama R. Gadgeel S. Sarkar F. Ahmad A. (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 4: 15.
56. Tejpar S. Prenen H. Mazzone M. (2012) Overcoming resistance to antiangiogenic therapies. Oncologist 17: 1039–1050.
57. Teng L. Xie J. Teng L. Lee R. (2012) Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv 9:901–908.
58. Thomas A. Maltzman J. Hassan R. (2013) Farletuzumab in lung cancer. Lung Cancer 80: 15–18.
59. Tian Y. Wu G. Xing J. Tang J. Zhang Y. Huang Z. et al. (2012) A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol 13: 30.
60. Toffoli G. Cernigoi C. Russo A. Gallo A. Bagnoli M. Boiocchi M. (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74: 193–198.
61. Toffoli G. Russo A. Gallo A. Cernigoi C. Miotti S. Sorio R. et al. (1998) Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79: 121–126.
62. Vergote I. Armstrong D. Scambia G. Fujiwara K. Gorbunova V. Schweizer C. et al. (2013) Double-blind, placebo-controlled study of weekly fartetuzumab with carboplatin / taxane in subjects with platinum-sensitive ovarian cancer in first relapse. Int J Gynecol Cancer 23(Suppl. 1): 11.
63. Vlahov I. Leamon C. (2012) Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem 23: 1357–1369.
64. Vlahov I. Santhapuram H. Kleindl P. Howard S. Stanford K. Leamon C. (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16: 5093–5096.
65. Weitman S. Lark R. Coney L. Fort D. Frasca V. Zurawski V. Jr et al. (1992 a) Distribution of the folate receptor GP 38 in normal and malignant cell lines and tissues. Cancer Res 52: 3396–3401.
66. Weitman S. Weinberg A. Coney L. Zurawski V. Jennings D. Kamen B. (1992 b) Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52: 6708–6711.
67. Westerhof G. Schornagel J. Kathmann I. Jackman A. Rosowsky A. Forsch R. et al. (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48: 459–471.
68. Zhao R. Min S. Wang Y. Campanella E. Low P. Goldman I. (2009) A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem 284: 4267–4274.